CD25 Target Antibody(Odyssey Therapeutics)

N/A

Report date: 2025/03/17 16:35:04

Base Information

Drug NameCD25 Target Antibody(Odyssey Therapeutics)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)
Mechanisms of ActionAnti-IL2RA
TargetsInterleukin-2 receptor alpha chain
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOdyssey Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesOdyssey Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A